EODData

MEMBERSHIP REGISTER LOG IN

FRA, 1C0: Celyad Oncology SA

30 Jan 2026
LAST:

0.1315

CHANGE:
 0.00		OPEN:
0.1315		HIGH:
0.1315		ASK:
0.0000		VOLUME:
0
CHG(%):
0.00		PREV:
0.1315		LOW:
0.1315		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
30 Jan 260.13150.13150.13150.13150
29 Jan 260.13150.13150.13150.13150
28 Jan 260.12850.13150.12850.131518
27 Jan 260.13250.13250.13250.13250
26 Jan 260.13350.13350.13350.13350
23 Jan 260.13100.13100.13100.13100
22 Jan 260.13750.13750.13750.13750
21 Jan 260.13800.13800.13800.13800
20 Jan 260.13700.13700.13700.13700
19 Jan 260.13500.13500.13500.13500

PROFILE

Name:Celyad Oncology SA
About:Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Address:Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
Website:https://celyad.com
ISIN:BE0974260896
LEI:549300ORR0M8XF56OI64

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.130.5%
MA10:0.131.8%
MA20:0.148.1%
MA50:0.1618.4%
MA100:0.2049.8%
MA200:0.29118.2%
STO9:7.14 
STO14:3.45 
RSI14:7.69 
WPR14:-96.55 
MTM14:-0.01
ROC14:-0.10 
ATR:0.01 
Week High:0.131.5%
Week Low:0.132.3%
Month High:0.2371.1%
Month Low:0.13118.2%
Year High:0.72450.6%
Year Low:0.132.3%
Volatility:149.40